Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (ISRCTN60181900) titled 'Phase 1 trial: Fortrea CRU code: 8526072' on Aug. 4.
Study Type: Interventional
Study Design:
Interventional (Other)
Primary Sponsor: CellCentric Limited
Condition:
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Other
Intervention:
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Recruitment Status: Not ...